hma combination strategies in mds: blc2, cd47 & tim-3 inhibitors
Published 1 year ago • 58 plays • Length 1:31Download video MP4
Download video MP3
Similar videos
-
2:52
jak inhibitor combination therapy for the treatment of myelofibrosis
-
1:38
a phase i study of wvt078, a bcma×cd3 bsab, with a gamma-secretase inhibitor (whg626) in r/r mm
-
0:47
overview of the phase iii enhance trial schema
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
1:50
hypomethylating agent based combinations in mds
-
1:57
combining molecular and clinical data to predict survival & transformation risk in patients with mds
-
13:39
key highlights in mds: treating lower-risk & higher-risk disease, trial updates, and more
-
11:18
medicalsystem- hematology analyzer ms-h650-maintenance training course
-
4:10
edisi khas 59 : pelajar skdh bersama team malaysia di international mathematics and science olympiad
-
9:25
improving mds management: new targets, drug combinations, and personalized and cellular therapies
-
1:14
how the ipss-m score helps personalizing treatment & combination therapies in hr-mds
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
2:06
outcomes & promising treatment options following hma failure in patients with hr-mds
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:22
key advances in mds management
-
1:29
automated tool for mds classification using the who & icc classification systems
-
2:16
current and future treatment approaches for hr-mds
-
1:07
the second revision of the international staging system for os in mm
-
1:32
next-generation sequencing for low-risk mds
-
1:49
the value of mass spectrometry in multiple myeloma & how this may impact clinical practice